NCT06877533 is a Phase 1 clinical trial of EOS006215 in Selected Advanced Solid Tumors, sponsored by iTeos Belgium SA.

Who is sponsoring NCT06877533?

NCT06877533 is sponsored by iTeos Belgium SA.

What drugs are being tested in NCT06877533?

Interventions in NCT06877533: EOS006215, Anticancer agent.

What condition does NCT06877533 study?

NCT06877533 studies Selected Advanced Solid Tumors.

Is NCT06877533 still recruiting?

NCT06877533 is currently terminated. Last updated 12 August 2025.

Last reviewed 2025-08-12 · How we verify

NCT06877533

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

Terminated Phase 1 Last updated 12 August 2025

What this trial tests

Phase 1 trial testing EOS006215 in Selected Advanced Solid Tumors in 3 participants. Terminated before completion.

Timeline

7 April 2025

Primary endpoint
10 July 2025

10 July 2025

Quick facts

Lead sponsor	iTeos Belgium SA
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	7 April 2025
Primary completion	10 July 2025
Estimated completion	10 July 2025
Sites	2 locations across United States

Drugs / interventions tested

EOS006215 — full drug profile →
Anticancer agent — full drug profile →

Conditions studied

Selected Advanced Solid Tumors — all drugs for Selected Advanced Solid Tumors →

Sponsor

iTeos Belgium SA — full company profile →

Who can join

18 and older, any sex, with Selected Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

TRM-010 is a first-in-human (FIH) clinical study designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of EOS006215, a fully human monoclonal antibody that binds to the triggering receptor expressed on myeloid cells 2 (TREM2). The study includes EOS006215 monotherapy and combination therapy with other anticancer agents in participants with advanced solid tumors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sepsis and the immunometabolic inflammatory response.
Paul SN, Nessel I, Puthucheary Z, Henson SM. · · 2026 · PMID 41629610 · DOI 10.1038/s44324-025-00095-w

Verify or expand the search:

Other recruiting trials for Selected Advanced Solid Tumors

Currently open trials in the same condition.

NCT03530397 — A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06877533 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by iTeos Belgium SA
Last refreshed: 12 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06877533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing